Presenters:
Sabine Hartvelt – Study Director of ReproTracker, Toxys
Marjory Moreau – Associate Director, Scitovation

About the webinar:
In vitro screening platforms are rapidly emerging to assess compounds’ developmental toxicity. These emerging technologies show a promising ability to predict the outcomes of in-life animal studies and to provide an attractive means for identifying developmental toxicants. Toxys developed the ReproTracker assay, a unique in vitro human stem cell reporter assay that accurately predicts the teratogenicity hazards of pharmaceuticals and chemicals. However, the ReproTracker assay currently does not consider the exposure of chemicals or drugs to the mother and fetus, which hampers adequate extrapolation of in vitro findings to relevant clinical dosing scenarios.

During this webinar, we will show how PBPK modeling can be applied to perform quantitative in vitro to in vivo extrapolation (IVIVE) of dosimetry and evaluate whether the ReproTracker assay can predict the in vivo developmental toxicity exposure levels of drugs. Two case studies will be presented that demonstrate the added value of the integrated approach, allowing for more human-relevant decision-making regarding hazard and exposure assessment.

In this webinar, you will learn about:
– How the ReproTracker assay works.
– The factors to consider when performing IVIVE.
– How to apply PBPK modeling to predict in vivo exposure levels using ReproTracker data.